IBCN 2018: The Impact of Chemotherapy on Immune Microenvironment
Rotterdam, The Netherlands (UroToday.com) William Y. Kim, MD presented work he took part in on the impact of chemotherapy on the immune microenvironment. In patients with bladder cancer, programmed death-ligand-1 (PD-L1) and programmed death-1 (PD-1) inhibitors have been shown to be effective in approximately 20% patients, with preliminary findings suggesting a level of immune infiltration and immune suppression within the tumor microenvironment correlates with response to these treatments.
IBCN 2018: PPARɣ-Mediated Repression of TFAP2A Expression Identifies an Important Transcriptional Circuit in Basal-Squamous Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) David J. DeGraff presented their work regarding Peroxisome Proliferator Activated Receptor Gamma (PPARɣ) in regulating Luminal-specific gene expression in bladder cancer. Bladder cancer tumor heterogeneity is now known. Recent identification of specific gene expression subtypes of bladder cancer provide an opportunity to identify high risk patients, and potentially tailor disease management.
IBCN 2018: Defining the Proteomic Landscape of Non – Muscle Invasive Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Antonia Vlahou presented work regarding proteomic definition of bladder cancer subtypes aiming to fill existing gaps and define optimal patient management schemes. They analyzed 98 fresh-frozen tissue samples from non-muscle invasive bladder cancer (58 pTa and 40 pT1) by high-resolution proteomics (LC-MS/MS).
IBCN 2018: MIBC Genomics in and Beyond TCGA and the PanCancerAtlas
Rotterdam, The Netherlands (UroToday.com) Gordon Robertson gave the IBCN Keynote Lecture regarding genomics in muscle-invasive bladder cancer (MIBC). Dr. Robertson was instrumental RNA differences in bladder cancer subtypes characterized by The Cancer Genome Atlas (TCGA). He reviewed 1) TCGA, 2) the TCGA MIBC project and 3) beyond TCGA.
IBCN 2018: Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Bogdan Czerniak, MD reported on the genome-wide characterization of the sarcomatoid variant of bladder cancer (SARC) including its miRNA, gene expression, and whole-exome mutational profiles, which identified unique molecular features associated with its aggressive nature that may be relevant for the early detection and treatment of this highly lethal variant of bladder cancer.
IBCN 2018: Genomic and Transcriptomic Heterogeneity in Bladder Cancer - Impact on Clinical Decision Making?
Rotterdam, The Netherlands (UroToday.com) Lars Dyrskjot discussed the impact of tumor heterogeneity in clinical decision-making. How heterogeneous are bladder tumors and how stable i.e molecular subtypes? Does biology of primary and metastatic tumors differ? How can we implement and disseminate genomics into the clinical setting?
IBCN 2018: Spatial and Temporal Heterogeneity in Bladder Cancer with Basal Phenotype
Rotterdam, The Netherlands (UroToday.com) Yves Allory discussed the spatial and temporal heterogeneity in bladder cancer with basal phenotype. CH5/6+ GATA3- has been found to be a useful tool to identify basal/squamous-like tumors. Spatial heterogeneity for dual CK5/6-GATA3 IHC can be observed and hypothesized in a fraction of tumors they have mixed molecular subtypes.